Avasimibe structure
|
Common Name | Avasimibe | ||
---|---|---|---|---|
CAS Number | 166518-60-1 | Molecular Weight | 501.721 | |
Density | 1.1±0.1 g/cm3 | Boiling Point | N/A | |
Molecular Formula | C29H43NO4S | Melting Point | 178-180° (Lee); mp 169.5-170.4° (Dozeman) | |
MSDS | USA | Flash Point | N/A |
Use of AvasimibeAvasimibe is an oral inhibitor of acyl-Coenzyme A:cholesterol acyltransferase (ACAT) with IC50s of 24 and 9.2 µM for ACAT1 and ACAT2, respectively. |
Name | [[2,4,6-tris(1-methylethyl)phenyl]acetyl]-, 2,6-bis(1-methylethyl)phenyl ester] sulfamic acid |
---|---|
Synonym | More Synonyms |
Description | Avasimibe is an oral inhibitor of acyl-Coenzyme A:cholesterol acyltransferase (ACAT) with IC50s of 24 and 9.2 µM for ACAT1 and ACAT2, respectively. |
---|---|
Related Catalog | |
References |
Density | 1.1±0.1 g/cm3 |
---|---|
Melting Point | 178-180° (Lee); mp 169.5-170.4° (Dozeman) |
Molecular Formula | C29H43NO4S |
Molecular Weight | 501.721 |
Exact Mass | 501.291290 |
PSA | 80.85000 |
LogP | 9.34 |
Appearance of Characters | white to tan |
Index of Refraction | 1.529 |
Storage condition | room temp |
Water Solubility | DMSO: ≥40mg/mL |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
|
RIDADR | NONH for all modes of transport |
---|---|
HS Code | 2935009090 |
~77% Avasimibe CAS#:166518-60-1 |
Literature: Journal of Medicinal Chemistry, , vol. 39, # 26 p. 5031 - 5034 |
~% Avasimibe CAS#:166518-60-1 |
Literature: Journal of Medicinal Chemistry, , vol. 39, # 26 p. 5031 - 5034 |
~% Avasimibe CAS#:166518-60-1 |
Literature: Journal of Medicinal Chemistry, , vol. 39, # 26 p. 5031 - 5034 |
~% Avasimibe CAS#:166518-60-1 |
Literature: Journal of Medicinal Chemistry, , vol. 39, # 26 p. 5031 - 5034 |
~% Avasimibe CAS#:166518-60-1 |
Literature: Journal of Medicinal Chemistry, , vol. 39, # 26 p. 5031 - 5034 |
~% Avasimibe CAS#:166518-60-1 |
Literature: Journal of Medicinal Chemistry, , vol. 39, # 26 p. 5031 - 5034 |
HS Code | 2935009090 |
---|---|
Summary | 2935009090 other sulphonamides VAT:17.0% Tax rebate rate:9.0% Supervision conditions:none MFN tariff:6.5% General tariff:35.0% |
Statin therapy alone and in combination with an acyl-CoA:cholesterol O-acyltransferase inhibitor on experimental atherosclerosis.
Pathophysiol. Haemost. Thromb. 36(1) , 9-17, (2007) The ability to modify the enzymatic processes involved in promoting atherosclerotic plaque disruption and to serially monitor atherosclerotic evolution could provide novel information in the managemen... |
|
Coronary circulatory function in patients with the metabolic syndrome.
J. Nucl. Med. 52(9) , 1369-77, (2011) The metabolic syndrome affects 25% of the U.S. population and greatly increases the risk of diabetes and coronary artery disease (CAD). We tested the hypothesis that the metabolic syndrome is associat... |
|
Avasimibe and atorvastatin synergistically reduce cholesteryl ester content in THP-1 macrophages.
Eur. J. Pharmacol. 451(1) , 11-7, (2002) Evidence suggests that the inhibition of both acyl-CoA:cholesterol acyltransferase and hydroxymethyl glutaryl-CoA reductase causes a synergistic direct antiatherosclerotic effect on the vessel wall. T... |
2,6-Diisopropylphenyl [(2,4,6-triisopropylphenyl)acetyl]sulfamate |
Sulfamic acid, N-[2-[2,4,6-tris(1-methylethyl)phenyl]acetyl]-, 2,6-bis(1-methylethyl)phenyl ester |
[2,6-di(propan-2-yl)phenyl] N-[2-[2,4,6-tri(propan-2-yl)phenyl]acetyl]sulfamate |
2,6-di(propan-2-yl)phenyl {[2,4,6-tri(propan-2-yl)phenyl]acetyl}sulfamate |
Avasimibe |
CI-1011 |